3/5
09:28 am
ocgn
Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.
Medium
Report
Ocugen (OCGN) had its "buy" rating reaffirmed by Chardan Capital. They now have a $7.00 price target on the stock.
3/4
01:43 pm
ocgn
Ocugen outlines 2026 BLA submission and expects three pivotal filings within three years amid leadership expansion [Seeking Alpha]
Medium
Report
Ocugen outlines 2026 BLA submission and expects three pivotal filings within three years amid leadership expansion [Seeking Alpha]
3/4
01:43 pm
ocgn
Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
Low
Report
Ocugen, Inc. (OCGN) Q4 2025 Earnings Call Transcript [Seeking Alpha]
3/4
12:52 pm
ocgn
Ocugen, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
Low
Report
Ocugen, Inc. Q4 2025 Earnings Call Summary [Yahoo! Finance]
3/4
10:57 am
ocgn
Ocugen Q4 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Ocugen Q4 Earnings Call Highlights [Yahoo! Finance]
3/4
10:17 am
ocgn
Ocugen (OCGN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Ocugen (OCGN) Q4 2025 Earnings Call Transcript [Yahoo! Finance]
3/4
08:43 am
ocgn
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
High
Report
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
3/4
08:15 am
ocgn
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Ocugen Provides Business Update with Fourth Quarter and Full Year 2025 Financial Results
3/2
07:35 am
ocgn
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa [Yahoo! Finance]
High
Report
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa [Yahoo! Finance]
3/2
07:02 am
ocgn
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
High
Report
Ocugen Announces Phase 3 liMeliGhT Enrollment Completion for OCU400, a Novel Modifier Gene Therapy for Broad Retinitis Pigmentosa
2/18
07:30 am
ocgn
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Medium
Report
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
2/18
07:02 am
ocgn
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Ocugen to Host Conference Call on Wednesday, March 4, 2026 at 8:30 A.M. ET to Discuss Business Updates and Fourth Quarter and Full Year 2025 Financial Results
2/11
08:37 pm
ocgn
What The Latest Developments Mean For Ocugen's Changing Valuation Story [Yahoo! Finance]
Low
Report
What The Latest Developments Mean For Ocugen's Changing Valuation Story [Yahoo! Finance]
2/11
07:42 am
ocgn
What's driving record CFO turnover? [Fortune]
Low
Report
What's driving record CFO turnover? [Fortune]
2/9
07:02 am
ocgn
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
Neutral
Report
Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
1/23
08:00 am
ocgn
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
Low
Report
Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
1/21
08:32 am
ocgn
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
Medium
Report
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
1/20
08:02 am
ocgn
Ocugen (NASDAQ:OCGN) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
Low
Report
Ocugen (NASDAQ:OCGN) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $7.00 price target on the stock.
1/16
12:56 pm
ocgn
Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data [Seeking Alpha]
Low
Report
Ocugen: Why I Don't Read Too Much Into The Selloff On Phase 2 GA Data [Seeking Alpha]
1/15
07:02 pm
ocgn
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
Medium
Report
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration [Yahoo! Finance]
1/15
08:15 am
ocgn
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
High
Report
Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
1/13
12:41 pm
ocgn
Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates [Yahoo! Finance]
Medium
Report
Why The Narrative Around Ocugen (OCGN) Is Shifting After New Fair Value Updates [Yahoo! Finance]
1/13
07:00 am
ocgn
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
Medium
Report
Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
1/12
06:46 am
ocgn
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy [Yahoo! Finance]
High
Report
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy [Yahoo! Finance]
1/12
06:30 am
ocgn
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
High
Report
Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy